ACOG
Alpha Cognition Inc.5.43
+0.42+8.48%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Payer timelines, sublingual details surface
Q&A drilled into payer pull-through timelines, expecting early Q2 traction from downstream plans under the second PBM contract and broad Q3 rollout, building on prepared remarks' 2-of-4 PBM milestone. Management outlined CONVERGE's polypharmacy analysis for LTC positioning with payers and detailed sublingual's Q2 PK study versus tablet, targeting dysphagia in 20% of patients for potential early-2027 clinic entry via 505(b)(2). Sales force expansion completed in March, honing psychiatry focus amid behavioral success stories. No walk-backs; tone confident on scaling. Sales force fully ramped. Investors track payer velocity next.
Key Stats
Market Cap
118.17MP/E (TTM)
-Basic EPS (TTM)
-1.38Dividend Yield
0%Recent Filings
8-K
Execs awarded equity grants
Alpha Cognition's Compensation Committee granted equity awards on January 9, 2026, to executives under its 2025 Stock Plan. CEO Michael McFadden received 190,549 RSUs vesting over three years, 177,576 options with quarterly vesting post-2027, and 76,220 performance units tied to stock prices from $12 to $28. Aligns leadership with shareholders. COO and interim CFO got similar packages scaled down.
10-Q
Q3 FY2025 results
Alpha Cognition posted Q3 revenue of $2.8M—$2.3M product, $0.5M licensing—versus zero last year, while YTD revenue hit $7.4M amid ZUNVEYL's U.S. launch post-FDA approval. Operating loss widened to $5.3M from $2.5M on $6.9M SG&A (up 372% y/y, derived), fueled by commercialization ramp-up and $1.1M stock-based comp; net loss narrowed to $1.3M from $1.9M thanks to $3.7M warrant liability gain. Cash burned $13.5M in operations (no capex for FCF), ending at $35.4M with no debt after repaying related-party note. Signed Jan 2025 CMS deal for Asia-Pacific rights, bagging $3M upfront (recognized Q1). Cash lasts 12+ months. Warrants pose dilution risk.
8-K
Auditor switch post-relocation
Alpha Cognition Inc. announced the resignation of its auditor Manning Elliott on October 10, 2025, due to licensing issues after relocating its headquarters from Canada to Texas. The company promptly engaged U.S.-licensed CBIZ CPAs as its new independent auditor, expecting no disruptions to financial reporting. No disagreements or reportable events marred the prior audits for 2023 and 2024. Transition smooths operations.
8-K
Priced $35M oversubscribed offering
Alpha Cognition priced an oversubscribed $35.0 million public offering of 5,600,000 common shares at $6.25 each, plus pre-funded warrants, on September 30, 2025, closing October 2. Funds target ZUNVEYL's commercial acceleration—sales, marketing, payer coverage. Cash hits ~$70 million. Insiders locked up 75 days.
IPO
Sector
Industry
ABOS
Acumen Pharmaceuticals, Inc.
2.10+0.04
ACIU
AC Immune SA
3.29+0.05
AGNPF
Algernon Pharmaceuticals Inc.
0.06-0.00
ALEC
Alector, Inc.
1.39-0.03
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANRO
Alto Neuroscience, Inc.
17.10+0.07
ATHE
Alterity Therapeutics Limited
3.07+0.06
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
IGC
IGC Pharma, Inc.
0.34+0.00
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01